Nurix Therapeutics, Inc. 8-K
Research Summary
AI-generated summary
Nurix Therapeutics Reports Q3 2026 Financial Results
What Happened
On July 9, 2026, Nurix Therapeutics, Inc. (NRIX) filed a Form 8‑K under Item 2.02 announcing the company’s financial results for the fiscal quarter ended May 31, 2026. The company issued a press release with those results, which is furnished as Exhibit 99.1 to the filing. The Form 8‑K was signed by Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer.
Key Details
- Filing date: July 9, 2026.
- Reporting period: fiscal quarter ended May 31, 2026.
- Disclosure type: Item 2.02 — Results of Operations and Financial Condition.
- Exhibit filed: Exhibit 99.1 (press release); cover page interactive XBRL (Exhibit 104).
- Form 8‑K signed by CEO Arthur T. Sands.
Why It Matters
This 8‑K signals Nurix has publicly disclosed its latest quarterly results — including earnings and other financial details — via a press release. Investors should read the Exhibit 99.1 press release for specific figures (revenue, net income/loss, cash position, and any commentary on guidance or operations) to assess near‑term performance and implications for the stock. The filing itself does not add new narrative beyond furnishing the press release.